a BP that already has a pipline of drugs that occupy the market that Leronlimab will might slow roll the finishing of approvals until they have squeezed out as much as they can in the pipline. They paid for that pipline and any new drug they buy waits in line. If we get a BP that does not have a conflict in their pipline, they will be eager to get it on the market to take market share and show their investors that the purchase was worth it.